Entrada Therapeutics, Inc. TRDA
6.16
(0.06)
(0.96%)
as of 25 Sep
- Market cap
- $242.2M
- P/E
- 0.0×
Follow TRDA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (54.09%) | (48.28%) | (39.13%) | (27.11%) |
+8 more TTM periods Free account |
|
| (44.35%) | (40.42%) | (31.81%) | (21.39%) | ||
ROIC |
(1,060.24%) | (697.14%) | (1,009.37%) | (547.44%) | |
Return on Tangible Assets |
(76.38%) | (65.35%) | (49.72%) | (32.06%) | |
Average Days of Receivables |
63.56 | 50.06 | 16.90 | 7.10 | |
Free Cash Flow per Share |
(3.18) | (3.15) | (3.13) | (3.13) | |
Free Cash Flow |
(134.35) | (131.64) | (129.55) | (129.80) | |
Capital Expenditures |
0.32 | 0.06 | (1.04) | (1.88) | |
Piotroski F-Score |
1.00 | 1.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(29.51%) | (25.05%) | (21.33%) | (19.16%) | |
Accounts Receivable Turnover |
4.70 | 4.05 | 10.47 | 32.39 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | (0.01) | (0.03) | |
Research and Development Expense of Revenue |
3,003.44% | 2,496.50% | 559.65% | 230.36% | |
Selling, General and Administrative Expense of Revenue |
863.64% | 712.79% | 161.48% | 67.23% | |
Share Based Compensation of Revenue |
413.32% | 335.76% | 77.14% | 32.43% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.79 | 0.89 | 1.24 | |
Depreciation/Fixed assets |
0.24 | 0.17 | 0.06 | (0.16) | |
Capex/Depreciation |
0.23 | 0.05 | (2.45) | 1.40 | |
Revenue per Share |
0.11 | 0.14 | 0.61 | 1.48 | |
Operating CF per Share |
(3.19) | (3.15) | (3.11) | (3.08) | |
Capex per Share |
0.01 | 0.00 | (0.03) | (0.05) | |
Capex to Sales |
(0.07) | (0.01) | 0.04 | 0.03 | |
Net Profit Margin |
(3,537.73%) | (2,895.05%) | (565.48%) | (168.16%) |
Columns are period end dates